HUB Investment Partners LLC Has $5.49 Million Stock Holdings in Gilead Sciences, Inc. $GILD

HUB Investment Partners LLC increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1,428.4% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 49,536 shares of the biopharmaceutical company’s stock after purchasing an additional 46,295 shares during the quarter. HUB Investment Partners LLC’s holdings in Gilead Sciences were worth $5,492,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of GILD. GoalVest Advisory LLC increased its position in shares of Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares in the last quarter. Activest Wealth Management increased its holdings in Gilead Sciences by 2,837.5% during the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares in the last quarter. Harbor Asset Planning Inc. acquired a new stake in shares of Gilead Sciences in the 2nd quarter valued at about $27,000. Howard Hughes Medical Institute acquired a new stake in shares of Gilead Sciences in the 2nd quarter valued at about $30,000. Finally, Putney Financial Group LLC lifted its holdings in shares of Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 94 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently issued reports on GILD. TD Cowen lifted their target price on Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a research report on Thursday, October 23rd. Scotiabank initiated coverage on shares of Gilead Sciences in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 price target for the company. Morgan Stanley boosted their price objective on shares of Gilead Sciences from $143.00 to $147.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. Sanford C. Bernstein restated an “outperform” rating on shares of Gilead Sciences in a report on Monday, November 3rd. Finally, Mizuho lifted their price target on shares of Gilead Sciences from $131.00 to $140.00 and gave the company an “outperform” rating in a research note on Friday, November 21st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $130.96.

Gilead Sciences Price Performance

Shares of GILD opened at $123.21 on Friday. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. The company’s fifty day simple moving average is $121.74 and its 200 day simple moving average is $115.62. Gilead Sciences, Inc. has a 1-year low of $88.57 and a 1-year high of $128.70. The company has a market cap of $152.86 billion, a price-to-earnings ratio of 19.10, a PEG ratio of 0.67 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. The firm had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter last year, the company posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.99%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $125.86, for a total value of $3,524,080.00. Following the transaction, the insider directly owned 107,193 shares in the company, valued at $13,491,310.98. The trade was a 20.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $125.08, for a total transaction of $625,400.00. Following the sale, the director owned 8,920 shares of the company’s stock, valued at approximately $1,115,713.60. This represents a 35.92% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 135,757 shares of company stock worth $16,616,127 in the last three months. 0.27% of the stock is owned by insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.